Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$1.7M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$266M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| GOOD JENNIFER L | Sep 9, 2024 | Sell | 1,840 | $3.0362 | $5,600 |
| GOOD JENNIFER L | Sep 6, 2024 | Sell | 4,219 | $3.0302 | $13,000 |
| GOOD JENNIFER L | Sep 5, 2024 | Sell | 40,277 | $3.1112 | $130,000 |
| GOOD JENNIFER L | Sep 4, 2024 | Sell | 10,981 | $3.0239 | $33,000 |
| GOOD JENNIFER L | Sep 3, 2024 | Sell | 3,863 | $3.0229 | $12,000 |
| Meeker David P | Aug 27, 2024 | Sell | 4,555 | $2.9314 | $13,000 |
| SCIASCIA THOMAS | Aug 19, 2024 | Sell | 16,496 | $2.9633 | $49,000 |
| SCIASCIA THOMAS | Aug 16, 2024 | Sell | 18,660 | $2.7567 | $51,000 |
| SCIASCIA THOMAS | Aug 15, 2024 | Sell | 12,745 | $2.7864 | $36,000 |
| SCIASCIA THOMAS | Aug 14, 2024 | Sell | 100 | $2.75 | $280 |
| SCIASCIA THOMAS | May 29, 2024 | Sell | 53,368 | $2.5504 | $140,000 |
| Delfini Lisa | May 22, 2024 | Sell | 4,350 | $2.6402 | $11,000 |
| GOOD JENNIFER L | May 20, 2024 | Sell | 25,037 | $2.8588 | $72,000 |
| GOOD JENNIFER L | May 10, 2024 | Sell | 4,578 | $2.9 | $13,000 |
| Delfini Lisa | Oct 11, 2023 | Sell | 785 | $2.02 | $1,600 |
| Delfini Lisa | Sep 11, 2023 | Sell | 711 | $2.2 | $1,600 |
| Delfini Lisa | Aug 11, 2023 | Sell | 682 | $2.36 | $1,600 |
| Delfini Lisa | Jul 11, 2023 | Sell | 687 | $2.34 | $1,600 |
| Delfini Lisa | May 11, 2023 | Sell | 562 | $2.89 | $1,600 |
| Delfini Lisa | Apr 11, 2023 | Sell | 840 | $1.839 | $1,500 |
| Delfini Lisa | Mar 13, 2023 | Sell | 892 | $1.7532 | $1,600 |
| Delfini Lisa | Feb 13, 2023 | Sell | 8,474 | $2.45 | $21,000 |
What's the latest insider transaction for Trevi Therapeutics ?
The most recent insider transaction for Trevi Therapeutics was conducted by GOOD JENNIFER L, who sold 1,840 shares on September 9, 2024 at a price of $3.04 per share.
Which insider has sold the most TRVI stock over the last two years?
GOOD JENNIFER L has sold the most TRVI stock in the last 2 years, with a total value of $270,000.
What is the total value of insider transactions for Trevi Therapeutics (TRVI) in the last 2 years?
The total value of insider transactions for Trevi Therapeutics in the last 2 years is negative, amounting to -$600,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Trevi Therapeutics 's market confidence?
Over the last 2 years, insider transactions for Trevi Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
